Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | F12 | P00748 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.42 |
| ▸ | C1S | P09871 | 2/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ACR | P10323 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9505480 | 0.97 | BLM (0.48) | F2F10F12F7F3 | |
| Diphenyl Ethanedioat SCHEMBL2254079 | 0.78 | PARP10 (0.46) | F2F10F12F7F3 | |
| Guanidine SCHEMBL27886402 | 0.78 | USP2 (0.49) | PRSS1KMT2APARP10ATMTDP1 | |
| Guanidine SCHEMBL4786082 | 0.78 | PARP10 (0.46) | PRSS1KMT2APARP10ATMTDP1 | |
| SCHEMBL29287939 | 0.78 | USP2 (0.45) | PRSS1KMT2APARP10ATMTDP1 | |
| SCHEMBL2665439 | 0.78 | LTA4H (0.45) | F2F10F12F7F3 | |
| SCHEMBL9748729 | 0.78 | LTA4H (0.45) | F2F10F12F7F3 | |
| SCHEMBL19381846 | 0.77 | PLAU (0.48) | F2BLMPRSS1PRSS2PRSS3 | |
| SCHEMBL347473 | 0.76 | LTA4H (0.43) | F2F10F12F7F3 | |
| Diphenylether SCHEMBL28792708 | 0.76 | LTA4H (0.67) | F2F10F12F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4186888-B1 | COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250228777-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2025-07-17 | — | — | US | disclosed |
| US-12324859-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-12263248-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| EP-4186888-A1 | COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220409536-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2022-12-29 | — | — | US | disclosed |
| EP-3596041-B1 | COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-110551105-B | Substituted triazoles useful as AXL inhibitors | 里格尔制药公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-114430775-A | Quinoline inhibitors of RAD52 and methods of use | 德雷克塞尔大学 | 2022-05-03 | — | — | CN | disclosed |
| US-6500824-B1 | PSYCHOSIS, OR PARALYSIS DUE TO ISCHEMIC SPINAL CORD INJURY. | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2002-12-31 | — | — | US | disclosed |
| US-6335352-B1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-01-01 | — | — | US | disclosed |
| EP-0623604-B1 | Oxa(Thia)-diazol-oxyphenylacrylates as pesticides | BAYER AG (DE) | 2001-08-08 | — | — | EP | disclosed |
| US-6204294-B1 | GUANIDINE CONTAINING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2001-03-20 | — | — | US | disclosed |
| WO-2000008027-A1 | KAPPA (OP2) OPIOID RECEPTOR ANTAGONISTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2000-02-17 | — | — | WO | disclosed |
| EP-0623604-A2 | Oxa(Thia)-diazol-oxyphenylacrylates as pesticides | BAYER AG (DE) | 1994-11-09 | — | — | EP | disclosed |
| EP-0325336-B1 | OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS PESTICIDES | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1993-08-04 | — | — | EP | disclosed |
| US-4929628-A | Oxadiazole compounds, their preparation and their use as pesticides | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ, B. V. (NL) | 1990-05-29 | — | — | US | disclosed |
| EP-0325336-A1 | Oxadiazole compounds, their preparation and their use as pesticides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1989-07-26 | — | — | EP | disclosed |
| US-4225618-A | FUNGICIDES, ARTHROPODICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324859-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | F2 4716/4885F10 4208/4885F12 2852/4885 |
| US-12263248-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | F2 4716/4885F10 4208/4885F12 2852/4885 |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | SIN3A, PLIN3, MSR1 | F2 4766/4885F10 4418/4885F12 3882/4885 |
| US-20220409536-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | F2 4716/4885F10 4208/4885F12 2852/4885 |
| US-20250228777-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | F2 4716/4885F10 4208/4885F12 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.